Teva Pharmaceutical Industries Ltd. has agreed to buy a 51% equity share of the genomic-analysis company. Immuneering Corporation.

Teva and Immuneering have worked together over the past several years in developing genetic biomarkers, therapy-specific gene expression signatures and realted work in characterizing non-biological complex drugs (NBCDs). Teva's majority holding in Immuneering provides right of first refusal in projects relating to the Teva’s stated objective of developing, personalizing and improving treatment of disorders of the central nervous system.

Source: Teva Pharmaceutical Industries